Orthopedic Oncology Market

Diagnostic Imaging is projected to lead at 74.0% share in 2026, followed by Stage II as set to secure 34.0% share of cancer stage in 2026. Rising musculoskeletal cancer incidence is expected to push hospitals toward advanced diagnostic imaging procurement tied to tumor staging and treatment planning. Adoption is likely to slow due to high capital costs for multi-modal imaging equipment and limited oncology imaging expertise in smaller hospital systems.